Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation

Transplantation. 2013 Aug 27;96(4):333-60. doi: 10.1097/TP.0b013e31829df29d.


Cytomegalovirus (CMV) continues to be one of the most common infections after solid-organ transplantation, resulting in significant morbidity, graft loss, and adverse outcomes. Management of CMV varies considerably among transplant centers but has been become more standardized by publication of consensus guidelines by the Infectious Diseases Section of The Transplantation Society. An international panel of experts was reconvened in October 2012 to revise and expand evidence and expert opinion-based consensus guidelines on CMV management, including diagnostics, immunology, prevention, treatment, drug resistance, and pediatric issues. The following report summarizes the recommendations.

Publication types

  • Consensus Development Conference
  • Practice Guideline

MeSH terms

  • Child
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control
  • Drug Resistance, Viral
  • Humans
  • International Agencies
  • Monitoring, Immunologic
  • Organ Transplantation / adverse effects*
  • Preoperative Care
  • Societies, Medical
  • Tissue Donors
  • Viral Vaccines / therapeutic use


  • Viral Vaccines